Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open-Label, Dose Escalation Study of the Safety and Pharmacokinetics of DMUC5754A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer

NCT01335958 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT01335958
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01335958 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open-Label, Dose Escalation Study of the Safety and Pharmacokinetics of DMUC5754A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer
Lead sponsor
Genentech, Inc.
Phase
Phase 1
Overall status
Completed
Start date
April 30, 2011
Completion date
February 28, 2014
Enrollment
77 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer, pancreatic cancer